Product Name :
2′,5′-Dideoxyadenosine (CAS 6698-26-6)
Synonym :
Application :
2′,5′-Dideoxyadenosine is a cell-permeable adenylate cyclase inhibitor
CAS:
6698-26-6
Purity:
≥98%
Molecular Weight:
235.2
Formula :
C10H13N5O2
Physical state:
Solid
solubility :
Soluble in DMSO (30 mg/mL), water (20 mg/mL) at 50° C, ethanol (10 mg/mL) at 50° C, and methanol (10 mg/mL – clear, colorless solution).
Shipping Condition :
Store at -20° C
Melting point:
176-178° C
SMILES:
C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C2N=CN=C3N)O
References:
:Synthesis and use of 3′-(azidoiodosalicyl) derivatives of 2′, 5′-dideoxyadenosine as photoaffinity ligands for adenylyl cyclase. | Shoshani, I., et al. 2000. Arch Biochem Biophys. 376: 221-8. PMID: 10729209Pyrimidinoceptor potentiation of macrophage PGE(2) release involved in the induction of nitric oxide synthase. | Chen, BC. and Lin, WW. 2000. Br J Pharmacol. 130: 777-86. PMID: 10864883Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. | Laux, WH., et al. 2004. J Biol Chem. 279: 13317-32. PMID: 14699161Enhancement of cellular adenosine triphosphate levels in PC12 cells by 2,5-dideoxyadenosine, a P-site inhibitor of adenylate cyclase. | Fujimori, H. and Pan-Hou, H. 2005. Biol Pharm Bull. 28: 358-60. PMID: 15684499Inhibition of adenylate cyclase attenuates adenosine receptor-mediated relaxation in coronary artery. | Sabouni, MH., et al. 1991. J Pharmacol Exp Ther. 259: 508-12. PMID: 1658301Fast manipulation of cellular cAMP level by light in vivo. | Schröder-Lang, S., et al. 2007. Nat Methods. 4: 39-42. PMID: 17128267Extracellular 3′,5′-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. | Dubey, RK., et al. 2010. J Pharmacol Exp Ther. 333: 808-15. PMID: 20194527Evidence for cAMP-independent bTREK-1 inhibition by ACTH and NPS-ACTH in adrenocortical cells.Price of Acid-PEG3-C2-Boc | Enyeart, JJ.((2-Iodoethoxy)methyl)benzene custom synthesis , et al. 2012. Mol Cell Endocrinol. 348: 305-12. PMID: 21952081Pharmacological distinction between soluble and transmembrane adenylyl cyclases. | Bitterman, JL., et al. 2013. J Pharmacol Exp Ther. 347: 589-98. PMID: 24091307Extracellular NAD(+) inhibits human neutrophil apoptosis. | Pliyev, BK., et al. 2014. Apoptosis. 19: 581-93. PMID: 24292505Role of adenylate cyclase in immunologic release of mediators from rat mast cells: agonist and antagonist effects of purine- and ribose-modified adenosine analogs. | Holgate, ST., et al. 1980. Proc Natl Acad Sci U S A. 77: 6800-4.PMID:33404136 PMID: 6256761Regulation of the catalytic component of adenylate cyclase. Potentiative interaction of stimulatory ligands and 2′,5′-dideoxyadenosine. | Florio, VA. and Ross, EM. 1983. Mol Pharmacol. 24: 195-202. PMID: 6310361Erythroid differentiation and growth inhibition of K562 cells by 2′,5′-dideoxyadenosine: synergism with interferon-alpha. | Ogawa, K., et al. 1995. Leuk Res. 19: 749-55. PMID: 7500653Isoproterenol antagonistic effect of 2′,5′-dideoxyadenosine in the isolated perfused guinea-pig heart. | Hartmann, M. and Schrader, J. 1993. J Mol Cell Cardiol. 25: 331-8. PMID: 8389889Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. | Balzarini, J., et al. 1997. FEBS Lett. 410: 324-8. PMID: 9237655